| |
3002 ApoE ε4 noncarrier study
|
|---|
|
PBO + BAP 0.5 (n = 38)
|
BAP 0.5 + BAP 0.5 (n = 62)
|
PBO + BAP 1.0 (n = 33)
|
BAP 1.0 + BAP 1.0 (n = 53)
|
|---|
|
ADAS-Cog, LS mean (SE)
|
12.44 (1.70)
|
10.38 (1.35)
|
10.54 (1.82)
|
10.31 (1.36)
|
|
LS mean difference
|
–2.05; P = 0.345
|
–0.22; P = 0.922
|
|
DAD, LS mean (SE)
|
–29.52 (3.48)
|
–28.00 (2.77)
|
–20.41 (3.74)
|
–23.21 (2.80)
|
|
LS mean difference
|
1.53; P = 0.733
|
–2.81; P = 0.550
|
|
NPI, LS mean (SE)
|
4.99 (2.60)
|
–0.01 (2.05)
|
4.23 (2.80)
|
6.57 (2.08)
|
|
LS mean difference
|
–4.99; P = 0.133
|
2.34; P = 0.505
|
|
MMSEa, LS mean (SE)
|
–4.86 (0.56)
|
–4.13 (0.44)
|
–4.63 (0.58)
|
–4.51 (0.46)
|
|
LS mean difference
|
0.73; P = 0.309
|
0.12; P = 0.872
|
-
ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
-
aDifference in MMSE score was between parent study baseline and extension study week 45
